All insulin manufacturers must price insulin pens at a dollar each in low- and middle-income countries

AMR remains a leading cause of death worldwide nearly a decade after UN member states agreed to make it a priority

MSF responds to WHO recommendation of three new regimens of shorter, all-oral TB regimens, outlines the importance of affordable access to these regimens.

MSF responds to WHO declaring mpox a PHEIC, outlines need for all components of an outbreak response and offers concrete actions to improve access and use of existing vaccines.

There were an estimated 1.3 million new HIV infections in 2023, but ViiV distributed only enough CAB-LA for approximately 13,000 people in 2023

Time for $5 campaign demands Cepheid reduce price of HIV, TB and hepatitis C tests to $5 each

MSF calls on pharmaceutical corporation Gilead to make groundbreaking HIV prevention drug lenacapavir affordable for all

Indian Patent Office’s rejection of J&J’s patent application on lifesaving paediatric TB drug bedaquiline significant step for increasing affordable access.

MSF welcomes withdrawal of patents on TB drug bedaquiline in South Africa

Following GeneXpert TB test price reduction, several low- and middle-income countries’ Ministries of Health request the same price reduction of other tests.

MSF urges the EU/EEA to remove access barriers to TB medicines and update policies and practices in line with WHO treatment guidelines.

MSF welcomes new amendments to the IHR, and urges INB negotiations to find a just framework for pandemic prevention, preparedness and response.

MSF is calling for the Gavi Board to ensure its next five-year strategy reaches the children in fragile and humanitarian settings who are missing vaccines

Ahead of the Symposium on Diabetes in Humanitarian Crises, MSF called on pharmaceutical corporations to bring down prices of insulin pens and newer diabetes drugs, so that everyone, everywhere can access optimal care

MSF urges public and non-profit actors to publish clinical trial costs to improve access to medical products

Colombia’s compulsory license can expand access to HIV drug dolutegravir

MSF calls on Danaher to drop all GeneXpert medical test prices to $5

With routine vaccination efforts failing to reach people in fragile and emergency settings, MSF is seeing low vaccination coverage and more outbreaks of vaccine-preventable diseases, like diphtheria and measles

MSF study in JAMA estimates the costs of production of new diabetes drugs and insulin pens

MSF demands Danaher and Cepheid drop the price of all GeneXpert tests to $5 each